Category: MacroGenics

MacroGenics (MGNX) recently disclosed its financial results for the second quarter, reporting a loss of $0.57 per share, slightly better than the expected $0.59 loss as per the Zacks Consensus Estimate. In comparison, the company had incurred a loss of $0.89 per share during the same period a year ago. These figures have been adjusted […]

MacroGenics Inc., headquartered in Rockville, Maryland, disclosed a loss of $36.3 million during the second quarter, translating to a loss of 57 cents per share. Despite this, the company outperformed predictions from Wall Street analysts. The consensus view from five analysts surveyed by Zacks Investment Research had anticipated a loss of 59 cents per share, […]

MacroGenics, Inc., a frontrunner in the biopharmaceutical industry, has carved a niche for itself by specializing in the discovery, development, manufacturing, and commercialization of innovative monoclonal antibody-based therapeutics for cancer treatment. With its deep-rooted expertise in advanced antibody technology platforms, MacroGenics has built a robust pipeline of product candidates that have broad therapeutic applications in […]